<DOC>
	<DOCNO>NCT02032212</DOCNO>
	<brief_summary>Electronic Vapour Products ( EVPs ) relatively new class consumer product otherwise know electronic cigarette . These may look like conventional cigarette contain tobacco . The 'vapour ' produce device typically consist humectant ( propylene glycol glycerol ) , nicotine , water , flavours . This trial evaluate pharmacokinetic profile EVP .</brief_summary>
	<brief_title>A Bioavailability Study Nicotine Delivered Electronic Vapour Product</brief_title>
	<detailed_description>The principal part study evaluate nicotine pharmacokinetic profile conventional cigarette , nicotine inhalator , unflavoured EVP flavour EVP . A second part investigate nicotine delivery EVP four different nicotine dos .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>BMI 1835kg/m2 Subjects must establish smoker Subjects must smoke five 30 cigarette per day least one year Subjects use nicotine replacement therapy within 14 day screen Subjects donate blood within 12 month precede study Subjects relevant illness history Subjects positive hepatitis HIV Subjects history drug alcohol abuse Subjects lung function test vital sign consider unsuitable Subjects try stop smoking</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>